GALIBRA NEUROSCIENCE
Galibra Neuroscience develops gene therapies for rare pediatric disorders caused by GABA imbalances, targeting the root genetic causes of conditions like developmental delay, autism, and epilepsy. The company focuses on gene replacement and gene editing approaches to restore GABA balance in the brain. Its pipeline leverages partnerships with academic institutions and patient advocacy groups to accelerate clinical translation.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Variants in over 20 genes involved in GABA synthesis, neurotransmission, degradation, and re-uptake lead to GABA imbalance, which is the root cause of many rare pediatric disorders. These disorders share common clinical manifestations including developmental delay, autism, and epilepsy, and currently lack disease-modifying treatments.
Solution
Galibra Neuroscience develops gene therapies designed to restore GABA balance in patients with GABA-related genetic disorders. The company's approach uses gene replacement therapy and gene editing techniques to target the specific genes responsible for GABA dysregulation. By precisely addressing the underlying genetic cause, the therapies aim to achieve functional GABA balance and provide disease-modifying benefits. The company collaborates with leading academic institutes and patient advocacy groups to streamline the translation of these novel therapies from bench to bedside.
Target Audience
Primary customers are pediatric patients with rare genetic GABA disorders and the healthcare providers and clinical research organizations treating them, as well as patient advocacy groups supporting these communities.
Features
- Gene replacement therapy and gene editing platforms targeting over 20 GABA-related genes
- Focus on rare pediatric disorders with shared clinical manifestations including developmental delay, autism, and epilepsy
- Precision medicine approach based on known gene function and location in GABA pathways
- Partnerships with academic institutions and patient advocacy groups to accelerate clinical development